禮來“減肥神藥”臨牀數據出爐!患者平均體重減輕20%以上
格隆匯4月29日丨據彭博,美國藥廠禮來(LLY.US)公佈減肥藥Tirzepatide一項晚期臨牀試驗數據,數據顯示,低劑量使用其藥物Tirzepatide平均減少體重15%,高劑量時平均減少22.5%。諾和諾德(NVO.US)的一種類似藥物Wegovy如果獲得批准,將與Tirzepatide,其平均減重率約為15%。禮來公司負責Tirzepatide的高級醫學主任Nadia Ahmad表示,該藥是目前研發階段首個能產生如此顯著減肥效果的藥物。她説,這是該領域的一個突破,證實我們正處於一個治療肥胖的全新時代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.